{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:10:52Z","timestamp":1791461452772,"version":"4.3.4"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.00775","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T14:28:52Z","timestamp":1598020132000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Management Issues in Myasthenia Gravis Patients Living With HIV: A Case Series and Literature Review"],"prefix":"10.3389","volume":"11","author":[{"given":"Jeannine M.","family":"Heckmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzaan","family":"Marais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/mus.24348","article-title":"Incidence of acetylcholine receptor-antibody-positive myasthenia gravis in South Africa","volume":"51","author":"Mombaur","year":"2015","journal-title":"Muscle Nerve."},{"key":"B2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.7196\/SAMJ.2019.v109i12.013895","article-title":"Descriptive analysis of World Health Organization-recommended second-line antiretroviral treatment: a retrospective cohort data analysis","volume":"109","author":"Gumede","year":"2019","journal-title":"S Afr Med J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S1474-4422(13)70002-4","article-title":"Manifestations of HIV infection in the peripheral nervous system","volume":"12","author":"Centner","year":"2013","journal-title":"Lancet Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.nmd.2007.07.002","article-title":"Myasthenia gravis in South Africans: racial differences in clinical manifestations","volume":"17","author":"Heckmann","year":"2007","journal-title":"Neuromuscul Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/mus.26172","article-title":"Myasthenic ophthalmoparesis: time To resolution after initiating immune therapies","volume":"58","author":"Europa","year":"2018","journal-title":"Muscle Nerve."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/mus.25154","article-title":"Characteristics of acetylcholine-receptor-antibody-negative myasthenia gravis in a South African cohort","volume":"54","author":"Huda","year":"2016","journal-title":"Muscle Nerve."},{"key":"B7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG composite: a valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1097\/00002030-200311210-00022","article-title":"Efavirenz-containing highly active antiretroviral therapy in an HIV-infected patient with myasthenia gravis","volume":"17","author":"Chiesa","year":"2003","journal-title":"AIDS."},{"key":"B10","first-page":"995","article-title":"HIV infection with myasthenia gravis","volume":"53","author":"Gorthi","year":"2005","journal-title":"J Assoc Physicians India."},{"key":"B11","doi-asserted-by":"publisher","first-page":"666","DOI":"10.5692\/clinicalneurol.48.666","article-title":"Anti-MuSK antibody positive myasthenia gravis with HIV infection successfully treated with cyclosporin: a case report","volume":"48","author":"Kurokawa","year":"2008","journal-title":"Rinsho Shinkeigaku."},{"key":"B12","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.clineuro.2011.03.019","article-title":"HIV-associated myasthenia gravis and impacts of HAART: one case report and a brief review","volume":"113","author":"Hung","year":"2011","journal-title":"Clin Neurol Neurosurg."},{"key":"B13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1212\/WNL.0b013e31820d6290","article-title":"Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis","volume":"76","author":"Kuntzer","year":"2011","journal-title":"Neurology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00415-015-7639-1","article-title":"MuSK myasthenia gravis as a manifestation of immune restoration disease in an HIV-positive patient","volume":"262","author":"Ragunathan","year":"2015","journal-title":"J Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e5769","DOI":"10.1097\/MD.0000000000005769","article-title":"Autoimmune diseases and HIV infection: a cross-sectional study","volume":"96","author":"Virot","year":"2017","journal-title":"Medicine."},{"key":"B16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.12659\/AJCR.903108","article-title":"Comorbid Human Immunodeficiency Virus (HIV) and Muscle-Specific Kinase (MuSK) myasthenia gravis: a case report and literature review","volume":"18","author":"Sherpa","year":"2017","journal-title":"Am J Case Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s12098-017-2593-9","article-title":"Myasthenia gravis in HIV positive girl","volume":"85","author":"Suthar","year":"2018","journal-title":"Indian J Pediatr."},{"key":"B18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/CND.0b013e3181fb1be7","article-title":"Comorbid HIV and myasthenia gravis: case report and review of the literature","volume":"12","author":"Knopf","year":"2010","journal-title":"J Clin Neuromuscul Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/(SICI)1097-4598(199805)21:5<680::AID-MUS26>3.0.CO;2-Y","article-title":"Ritonavir-associated myasthenia gravis","volume":"21","author":"Saadat","year":"1998","journal-title":"Muscle Nerve."},{"key":"B20","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1017\/S0317167100034119","article-title":"Seronegative myasthenia gravis and human immunodeficiency virus infection: response to intravenous gamma globulin and prednisone","volume":"25","author":"Strong","year":"1998","journal-title":"Can J Neurol Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mus.10133","article-title":"Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis","volume":"26","author":"De Feo","year":"2002","journal-title":"Muscle Nerve."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1212\/WNL.0000000000003821","article-title":"Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients","volume":"88","author":"Lloyd","year":"2017","journal-title":"Neurology."},{"key":"B23","first-page":"456","article-title":"Occurrence of myasthenia in HIV infection. Two cases","volume":"144","author":"Tiab","year":"1993","journal-title":"Ann Med Interne."},{"key":"B24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jneuroim.2019.05.004","article-title":"Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis","volume":"332","author":"Jing","year":"2019","journal-title":"J Neuroimmunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.021","article-title":"Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis","volume":"311","author":"Jing","year":"2017","journal-title":"J Neuroimmunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"776","DOI":"10.4102\/sajhivmed.v18i1.776","article-title":"Adult antiretroviral therapy guidelines 2017","volume":"18","author":"Meintjes","year":"2017","journal-title":"South Afr J HIV Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol"},{"key":"B29","first-page":"765","article-title":"High-dose immunosuppressive therapy in generalised myasthenia gravis\u2013a 2-year follow-up study","volume":"91","author":"Heckmann","year":"2001","journal-title":"S Afr Med J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1471-2334-14-71","article-title":"Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: a case-control study","volume":"14","author":"Van der Watt","year":"2014","journal-title":"BMC Infect Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1471-2334-6-59","article-title":"CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa","volume":"6","author":"Lawn","year":"2006","journal-title":"BMC Infect Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12981-015-0073-8","article-title":"Sensory neuropathy and metabolic risk factors in human immune deficiency virus infected South Africans receiving protease inhibitors","volume":"12","author":"Vermaak","year":"2015","journal-title":"AIDS Res Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jns.2005.01.003","article-title":"Thiopurine methyltransferase (TPMT) heterozygosity and enzyme activity as predictive tests for the development of azathioprine-related adverse events","volume":"231","author":"Heckmann","year":"2005","journal-title":"J Neurol Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/WCO.0b013e328346d47d","article-title":"Managing the risks of immunosuppression","volume":"24","author":"Riminton","year":"2011","journal-title":"Curr Opin Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijid.2016.11.006","article-title":"Preventive therapy for latent tuberculosis infection-the promise and the challenges","volume":"56","author":"Fox","year":"2017","journal-title":"Int J Infect Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e022445","DOI":"10.1136\/bmjopen-2018-022445","article-title":"Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines","volume":"8","author":"Hasan","year":"2018","journal-title":"BMJ Open."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/thoraxjnl-2015-207991","article-title":"What defines latent infection with Mycobacterium tuberculosis in patients with autoimmune diseases?","volume":"71","author":"Sester","year":"2016","journal-title":"Thorax."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1093\/clinids\/20.6.1577","article-title":"Myasthenia gravis and systemic lupus erythematosus in association with human immunodeficiency virus infection","volume":"20","author":"Maradona","year":"1995","journal-title":"Clin Infect Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"722","DOI":"10.5588\/ijtld.10.0284","article-title":"Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV\/AIDS era: a systematic review","volume":"15","author":"van der Watt","year":"2011","journal-title":"Int J Tuberc Lung Dis."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00775\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T14:28:54Z","timestamp":1598020134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00775\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,21]]},"references-count":39,"alternative-id":["10.3389\/fneur.2020.00775"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.00775","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,21]]},"article-number":"775"}}